Skip to main content
Biocorp logo

Biocorp — Investor Relations & Filings

Ticker · ALCOR ISIN · FR0012788065 LEI · 969500TKUAME6031UQ32 PA Manufacturing
Open in API
Filings indexed 235 across all filing types
Latest filing 2017-02-08 Board/Management Inform…
Country FR France
Listing PA ALCOR

About Biocorp

https://biocorpsys.com

Biocorp designs, develops, and manufactures medical devices and drug delivery systems for the pharmaceutical industry. The company specializes in combining precision engineering with connected technologies to improve patient treatment adherence and outcomes. Its portfolio includes both connected and non-connected devices, such as smart caps for inhalers (Inspair), pen injectors, and systems for drug reconstitution and safety. Biocorp manages the entire value chain, from research and development to manufacturing and final packaging, leveraging its expertise in plastics processing and advanced technological innovation. Since October 2023, Biocorp has been a subsidiary of Novo Nordisk.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 1% confidence The document is a press release dated February 8, 2017, announcing the promotion of Eric Dessertenne to the position of Deputy Chief Executive Officer (Directeur Général Délégué) at BIOCORP. This announcement details changes in senior management personnel. Based on the provided definitions, this clearly falls under 'Board/Management Information' (Code: MANG), which covers announcements of changes in the company's board of directors or senior management.
2017-02-08 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release announcing that BIOCORP will present its innovations at the 20th Pharmapack exhibition in February 2017. It details the company's participation, booth location, and speaking engagements. This type of announcement, which informs the public about participation in an industry event, presentation schedules, or general corporate news that doesn't fit a specific financial filing category (like 10-K, ER, or DIV), is best classified as a general Regulatory Filing or Announcement. Since it is not a formal financial report, a management change, or a shareholder vote result, the most appropriate fallback category is 'Regulatory Filings' (RNS), as it serves as a general corporate communication.
2017-01-25 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release ("Communiqué de presse") dated January 25, 2017, announcing that BIOCORP will present its innovations at the Pharmapack event on February 1st and 2nd, 2017. It details the company's participation, stand location, product showcases (NewGuard), and speaking sessions by the Deputy CEO. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is an announcement about future corporate activities and participation in an industry event. Since it is a general corporate announcement that doesn't fit the specific categories like MANG, DIV, or CAP, and it is not a transcript (CT) or a presentation (IP), the most appropriate general category for corporate news announcements that don't fit elsewhere is Regulatory Filings (RNS), which often serves as a catch-all for press releases not covered by other specific codes.
2017-01-25 French
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 1% confidence The document is a short press release titled "BIOCORP: 2017 financial calendar". It explicitly lists the dates for future events, including the '2016 full-year results' publication, the 'Annual shareholders meeting', and the '2017 first-half results' publication. Since the document's primary function is to announce *when* other reports or meetings will occur, rather than being the report itself (like a 10-K or IR), it fits the definition of a Report Publication Announcement (RPA). The document length (2558 chars) is also short, supporting the RPA classification based on the 'MENU VS MEAL' rule.
2017-01-10 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is a press release titled "BIOCORP : Agenda financier 2017" (Financial Agenda 2017). It explicitly lists future dates for key corporate events: Annual Results (Résultats annuels 2016), Annual General Meeting (Assemblée Générale), and Half-Year Results (Résultats semestriels 2017). Since this document is announcing the schedule of future corporate events and reports, rather than being the report itself or a transcript, it fits best under the category of a general announcement regarding corporate activities or future reporting schedules. Given the options, it is not a specific report (like 10-K, IR, ER), nor is it a management change (MANG) or dividend notice (DIV). It is an announcement about future corporate events, including the AGM date. While it mentions the AGM date, it is primarily an overall financial calendar announcement. The closest fit among the specific codes that deal with announcements of future events or reports is Report Publication Announcement (RPA), as it announces when reports will be published, or Regulatory Filings (RNS) as a general announcement. Since it is a forward-looking schedule announcement, and not a specific report, RPA is a strong candidate, but RNS is the general fallback for non-specific regulatory/corporate announcements. However, since it specifically details the date of the 'Assemblée Générale' (AGM), and the document is very short (2663 chars) and serves as a notice, it is best classified as a general corporate announcement. Given the options, and the nature of announcing future dates for financial reporting and the AGM, it is a general corporate communication. I will classify it as RNS (Regulatory Filings) as the most appropriate general announcement category when a more specific announcement type (like DIV or ER) doesn't fit, although it is closely related to future AGM/ER events.
2017-01-10 French
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Share Issue/Capital Change Classification · 1% confidence The document is a press release ("Communiqué de presse") announcing the annual review ("Bilan annuel") of a liquidity contract ("contrat de liquidité") managed by a brokerage firm (TSAF). It details the holdings (shares and cash) in the liquidity account as of December 31, 2016, and compares them to the previous semi-annual review. This type of announcement, which reports on specific financial arrangements or transactions rather than comprehensive financial results (10-K, IR) or management changes (MANG), fits best under the general category for regulatory announcements or specific financial updates. Since it is a specific report on a financial mechanism (liquidity contract) and not a general earnings release (ER) or a major capital change (CAP/SHA), it is most closely related to specific financial disclosures. Given the options, this is a specific financial disclosure that doesn't fit perfectly into the main categories like 10-K, ER, or IR. However, it is a formal report on a financial arrangement. If we consider the nature of the disclosure—a formal report on a specific financial arrangement (liquidity contract)—it is a specific financial update. Since there isn't a dedicated 'Liquidity Contract Update' code, we must choose the closest fit. It is not a dividend (DIV), a major shareholding change (MRQ), or a transaction in own shares (POS) in the sense of a buyback program announcement, but rather a report on the status of an existing arrangement. Given the context of financial reporting, and since it is a formal, periodic report on a financial mechanism, it is often grouped with other specific financial disclosures. Since it is a formal report detailing the status of a financial arrangement, and not a general announcement of a report (RPA), it is classified as a specific financial disclosure. The closest fit among the provided codes for a specific, non-earnings financial status report is often a general regulatory filing (RNS) or, if it were more comprehensive, perhaps an Interim Report (IR), but this is too narrow. Given the options, and recognizing this as a specific, periodic financial disclosure that isn't a standard earnings report, RNS (Regulatory Filings) serves as the most appropriate fallback for specific, non-standard regulatory disclosures, although it is a very specific type of financial update. Upon re-evaluation, this document reports on the status of a liquidity contract, which is a specific financial arrangement. It is not a standard earnings release, annual report, or management discussion. It is a formal disclosure of financial status related to market making. This type of specific, periodic financial disclosure often falls under general regulatory announcements (RNS) when a more specific code is unavailable. I will use RNS as the best fit for a specific, non-standard regulatory/financial disclosure.
2017-01-09 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.